Thanks for participating in our interactive
clinical knowledge question.
Question: Xanomeline-trospium, a new antipsychotic agent for schizophrenia, has a lower risk of which adverse effects compared with other agents?
{{APercent}}% of
Medical Professionals
Chose A
{{BPercent}}% of
Medical Professionals
Chose B
{{CPercent}}% of
Medical Professionals
Chose C
{{DPercent}}% of
Medical Professionals
Chose D
Correct Answer: D. Xanomeline-trospium is the first antipsychotic agent to exclusively target muscarinic receptors. Adverse effects include urinary retention, increased heart rate, decreased gastric motility, nausea, vomiting, constipation, and hypertension. However, it is associated with fewer side effects (eg, extrapyramidal symptoms) than most commonly used dopamine-blocking agents and has minimal effect on the QTc interval. To view the related What's New topic in UpToDate, click here. (“What’s new in psychiatry”);
No matter how you answered, it can often be helpful to have a clinical decision support tool to confirm your knowledge or keep up with the latest changes in medicine.
With a personal subscription to UpToDate, you’ll improve your clinical knowledge by having access to over 12,300 clinical topics spanning 25 medical specialties.
As a Doximity member, you can SAVE $30 on an annual or longer personal subscription to UpToDate using promo code DOX30 for a limited time only.
Subscribe today with special offer